Applied Therapeutics downgraded by UBS with a new price target
$APLT
Biotechnology: Pharmaceutical Preparations
Health Care
UBS downgraded Applied Therapeutics from Buy to Neutral and set a new price target of $2.00 from $13.00 previously
Get the next $APLT alert in real time by email
Get the next $APLT alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $APLT
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2024 | Outperform → Mkt Perform | William Blair | |
| 12/2/2024 | $13.00 → $2.00 | Buy → Neutral | UBS |
| 11/29/2024 | $12.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/31/2024 | Outperform | William Blair | |
| 3/26/2024 | $12.00 | Outperform | RBC Capital Mkts |
| 2/22/2024 | $12.00 | Outperform | Leerink Partners |
| 1/4/2022 | $44.00 → $7.00 | Overweight → Equal-Weight | Barclays |
| 8/27/2021 | $10.00 | Neutral → Sell | Goldman Sachs |
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceutical and medical device industries. In this newly created role, she will report directly to the executive leadership team and Executive Chairman, and will be responsible for overseeing all quality matters, including Good Manufacturing Practices, Good Laboratory Practices, and Good Clinical Practices. "We are pleased to
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John
Applied Therapeutics downgraded by William Blair
William Blair downgraded Applied Therapeutics from Outperform to Mkt Perform
Applied Therapeutics downgraded by UBS with a new price target
UBS downgraded Applied Therapeutics from Buy to Neutral and set a new price target of $2.00 from $13.00 previously
Applied Therapeutics downgraded by RBC Capital Mkts with a new price target
RBC Capital Mkts downgraded Applied Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $12.00 previously
Kanter Stacy J. bought $65,367 worth of shares (30,000 units at $2.18), increasing direct ownership by 91% to 63,000 units (SEC Form 4)
4 - Applied Therapeutics Inc. (0001697532) (Issuer)
Chief Commercial Officer Hooks Corwin Dale was granted 250,000 shares, increasing direct ownership by 83% to 550,000 units (SEC Form 4)
4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
Officer Funtleyder Leslie D. was granted 350,000 shares, increasing direct ownership by 90% to 740,459 units (SEC Form 4)
4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
Officer Chinoporos Constantine was granted 350,000 shares, increasing direct ownership by 129% to 621,436 units (SEC Form 4)
4 - Applied Therapeutics, Inc. (0001697532) (Issuer)
SEC Form SCHEDULE 13G filed by Applied Therapeutics Inc.
SCHEDULE 13G - Applied Therapeutics, Inc. (0001697532) (Subject)
SEC Form SCHEDULE 13G filed by Applied Therapeutics Inc.
SCHEDULE 13G - Applied Therapeutics, Inc. (0001697532) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by Applied Therapeutics Inc.
SCHEDULE 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceutical and medical device industries. In this newly created role, she will report directly to the executive leadership team and Executive Chairman, and will be responsible for overseeing all quality matters, including Good Manufacturing Practices, Good Laboratory Practices, and Good Clinical Practices. "We are pleased to
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05) Sustained, statistically significant reduction in sorbitol in govorestat-treated patients vs. placebo (p<0.001) Highly statistically significant effects on the CMT Health Index (CMT-HI) patient reported outcome measure (p=0.01), with benefit of govorestat on categories of lower limb function, mobility, fatigue, pain, sensory function, and upper limb function Company plans to request a pre-NDA meeting with the neurology division of the US FDA regarding potential approval based on current data Company to host investor conference call and webcast today at 8:3
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker dataGovorestat treatment improved activities of daily living, behavior, cognition, fine motor skills, adaptive skills and tremor vs. placeboCompany plans to request a pre-NDA meeting with the FDA as soon as possible to discuss a potential NDA submission in second half of 2023; plans to submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in mid-2023 NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company
Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency
The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and EuropeAT-007 reduced sorbitol by a mean of 52%, or approximately 16,000 ng/ml, over a 90 day period, which was highly statistically significant vs. placebo (p<0.001)Company to host conference call to discuss results at 8:30am Eastern NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medi
Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.
SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)
Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.
SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)
Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.
SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)